The global 3D bioprinting market size is expected to reach USD 4.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.8% from 2021 to 2028. Rising cases of COVID-19 and increasing prevalence of chronic diseases are some of the major factors contributing towards market growth.

The COVID-19 epidemic is ever increasing since it was first identified in China in December 2019. Until January 12, 2021, more than 91.5 million cases of COVID-19 were reported globally, with more than 1,956,880 deaths, across the globe. This pandemic has fast tracked the development of vaccine and drug testing. There are currently more than 50 COVID-19 vaccine candidates in trials.

In the meantime, various 3D bioprinting companies are focused on research and development of artificial tissues. With the help of U-FAB, and other bioprinting technologies, CLECELL company has created respiratory epithelium artificial tissue which will help to prevent infection and tissue injury through the use of the mucociliary elevator. This pandemic has not only affected the well-being of people, but has also affected the economy, and various other healthcare infrastructures worldwide. This has severely disrupted the medical devices and pharmaceutical supply chains across the world. In such critical situation, various 3D bioprinting companies have created a global movement to supply emergency medical equipment such as ventilators, and personal protection equipment (PPE), to the healthcare workers.

North America held the highest share of the market, accounting for about 32.4% of the market share in 2020. Increasing adoption of 3D bioprinting for the production of medical products is expected to be one of the major factors contributing to market growth in this region. Whereas, Asia Pacific is anticipated to witness technological developments in pharmaceutical and biopharmaceutical sectors.